Affiliation:
1. Wockhardt Research Center, Aurangabad, India 431210
2. Hershey Medical Center, Hershey, Pennsylvania 17033
Abstract
ABSTRACT
WCK 771 demonstrated MIC
50
and MIC
90
s of 0.03 and 1 μg/ml, respectively, against 297 recent U.S. community-acquired and hospital strains of
Staphylococcus aureus
, irrespective of quinolone or glycopeptide resistance. Against quinolone-resistant strains, MIC
90
s of WCK 771 and moxifloxacin were 1 and 16 μg/ml, respectively.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference17 articles.
1. Appelbaum, P. C. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents30:398-408.
2. The Anti-Methicillin-Resistant
Staphylococcus aureus
Quinolone WCK 771 Has Potent Activity against Sequentially Selected Mutants, Has a Narrow Mutant Selection Window against Quinolone-Resistant
Staphylococcus aureus
, and Preferentially Targets DNA Gyrase
3. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically approved standard 7th ed. 2006 vol. 26.
4. Ferrero, L., B. Cameron, B. Manse., D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol.4:651-653.
5. In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献